Ovid Therapeutics Inc Financials

OVID

FY2025 annual

Revenue $7.3M +1181.3% YoY

Net Income -$17.4M +34.1% YoY

EPS (Diluted) Not reported for FY2025

Free Cash Flow -$38.3M +31.6% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Ovid Therapeutics Inc (OVID) reported $7.3M in revenue for fiscal year 2025, up 1181.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OVID FY2025 2026-08-26

The business remains a development-stage cash consumer, with operating investment increasingly funded through external capital rather than sales.

FY2025 operating cash flow matched free cash flow at -$38.3M despite no reported capital expenditures, linking cash use to ongoing operations—especially $25.6M of research and development—rather than physical expansion. That gap between development spending and current revenue explains why reduced losses have not yet produced self-funded operations.

Reported revenue reached $7.3M in FY2025 while research and development remained $25.6M; the cost structure is still designed to fund development ahead of meaningful revenue generation. The contrast with FY2021, when revenue was $208.4M and net income was $122.8M, shows that earlier earnings scale did not persist into later periods.

FY2025 financing cash flow contributed $75.2M, while shares outstanding nearly doubled; the pairing is consistent with equity financing being an important funding channel for operating cash use. The reported liquidity comparison stood at 28.3 months of the latest annual outflow, a point-in-time balance comparison rather than evidence that operations currently fund themselves.

Financial Health Signals

Financial Health Score 33/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ovid Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Ovid Therapeutics Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 10/100.

Growth

Ovid Therapeutics Inc's revenue surged 1181.3% year-over-year to $7.3M, reflecting rapid business expansion. This strong growth earns a score of 1/100.

Leverage

Ovid Therapeutics Inc carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 8.97, Ovid Therapeutics Inc holds $8.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 96/100.

Cash Flow

Ovid Therapeutics Inc's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.

Returns

Ovid Therapeutics Inc posts a -13.3% return on equity (ROE), meaning it loses $13 for every $100 of shareholders' equity. This results in a returns score of 14/100. This is up from -38.7% the prior year.

Altman Z-Score Safe

12.84

Ovid Therapeutics Inc scores 12.84, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($546.8M) relative to total liabilities ($20.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Ovid Therapeutics Inc passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Ovid Therapeutics Inc reported a net loss of $17.4M while operations used $38.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$7.3M

YoY+1181.3%

5Y CAGR-10.5%

Ovid Therapeutics Inc generated $7.3M in revenue in fiscal year 2025. This represents an increase of 1181.3% from the prior year.

EBITDA

-$42.2M

YoY+31.2%

Ovid Therapeutics Inc's EBITDA was -$42.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.2% from the prior year.

Net Income

-$17.4M

YoY+34.1%

Ovid Therapeutics Inc reported -$17.4M in net income in fiscal year 2025. This represents an increase of 34.1% from the prior year.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$38.3M

YoY+31.6%

Ovid Therapeutics Inc recorded an outflow of $38.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 31.6% from the prior year.

Cash & Debt

$13.2M

YoY-50.0%

5Y CAGR-28.8%

10Y CAGR-15.4%

Ovid Therapeutics Inc held $13.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

132M

YoY+85.5%

5Y CAGR+14.9%

Ovid Therapeutics Inc had 132M shares outstanding in fiscal year 2025. This represents an increase of 85.5% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-13.3%

YoY+25.4pp

5Y CAGR+172.4pp

10Y CAGR+6.0pp

Ovid Therapeutics Inc's ROE was -13.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 25.4 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$25.6M

YoY-30.4%

5Y CAGR-16.6%

10Y CAGR+14.5%

Ovid Therapeutics Inc invested $25.6M in research and development in fiscal year 2025. This represents a decrease of 30.4% from the prior year.

Capital Expenditures

YoY-100.0%

Ovid Therapeutics Inc reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

OVID Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

OVID quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Revenue	$1.6M	$7.3M+1181.3%	$566K+44.4%	$392K-73.9%	$1.5M-99.3%	$208.4M+1551.6%	$12.6M	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.6M	$25.6M-30.4%	$36.8M+28.6%	$28.6M+16.1%	$24.6M-47.6%	$46.9M-26.0%	$63.4M+50.4%	$42.2M+24.8%	$33.8M-32.4%	$50.0M+421.3%	$9.6M+45.0%	$6.6M
SG&A Expenses	$26.3M	$24.1M-6.1%	$25.7M-17.4%	$31.1M-4.2%	$32.4M-12.9%	$37.2M+21.6%	$30.6M+59.1%	$19.3M+0.6%	$19.1M+27.3%	$15.0M+16.1%	$12.9M+96.8%	$6.6M
Operating Income	-$58.4M	-$42.4M+31.4%	-$61.9M-4.4%	-$59.3M-6.7%	-$55.5M-144.7%	$124.2M+252.5%	-$81.4M-32.6%	-$61.4M-16.0%	-$52.9M+18.6%	-$65.0M-188.5%	-$22.5M-70.8%	-$13.2M
Income Tax	$0	$0	$0	$0	$0-100.0%	$1.3M	$0	$0	$0	$0	N/A	N/A
Net Income	-$34.5M	-$17.4M+34.1%	-$26.4M+49.5%	-$52.3M+3.5%	-$54.2M-144.1%	$122.8M+251.6%	-$81.0M-34.0%	-$60.5M-16.3%	-$52.0M+19.8%	-$64.8M-189.1%	-$22.4M-70.3%	-$13.2M
EPS (Diluted)	—	N/A	N/A	-$0.74+3.9%	-$0.77-143.8%	$1.76+226.6%	-$1.39	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$733K	$0-100.0%	$718K+443.9%	$132K-97.9%	$6.3M+4724.6%	$130K+71.1%	$76K-56.1%	$173K
R&D Expenses	$10.0M-10.9%	$11.2M+69.7%	$6.6M+12.2%	$5.9M-9.2%	$6.5M-2.9%	$6.7M+12.2%	$5.9M-24.5%	$7.9M
SG&A Expenses	$6.5M-2.9%	$6.7M+3.8%	$6.4M-5.3%	$6.8M+39.0%	$4.9M-19.0%	$6.0M+23.7%	$4.9M-12.2%	$5.5M
Operating Income	-$15.7M+12.0%	-$17.8M-45.2%	-$12.3M+1.8%	-$12.5M-146.9%	-$5.1M+59.6%	-$12.6M-17.0%	-$10.7M+18.9%	-$13.2M
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$15.0M+11.6%	-$17.0M-275.6%	$9.7M+179.6%	-$12.2M-159.6%	-$4.7M+54.2%	-$10.2M-11.0%	-$9.2M+34.2%	-$14.0M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.20

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

OVID Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

OVID quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Total Assets	$150.9M+63.8%	$92.2M-36.0%	$144.0M-7.2%	$155.3M-20.2%	$194.5M+156.2%	$75.9M-6.1%	$80.8M+69.7%	$47.6M-46.7%	$89.5M+68.7%	$53.0M	N/A
Current Assets	$74.4M+32.9%	$55.9M-49.0%	$109.6M-16.6%	$131.4M-31.0%	$190.5M+154.5%	$74.8M-6.2%	$79.8M+80.3%	$44.3M-50.0%	$88.6M+69.0%	$52.4M	N/A
Cash & Equivalents	$13.2M-50.0%	$26.3M-2.7%	$27.0M-39.7%	$44.9M-76.1%	$187.8M+160.7%	$72.0M+71.9%	$41.9M+14.8%	$36.5M-58.1%	$87.1M+67.7%	$51.9M-25.7%	$69.9M
Total Liabilities	$20.3M-15.3%	$23.9M-57.4%	$56.2M+144.6%	$23.0M+55.4%	$14.8M-54.2%	$32.3M+198.5%	$10.8M+22.3%	$8.8M+46.9%	$6.0M+61.3%	$3.7M	N/A
Current Liabilities	$8.3M-21.2%	$10.5M-8.3%	$11.5M+64.1%	$7.0M-52.8%	$14.8M-32.9%	$22.1M+109.5%	$10.5M+19.1%	$8.8M+46.9%	$6.0M+61.3%	$3.7M	N/A
Total Equity	$130.7M+91.5%	$68.2M-22.3%	$87.8M-33.6%	$132.3M-26.4%	$179.7M+312.0%	$43.6M-37.7%	$70.0M+80.4%	$38.8M-53.5%	$83.4M+69.3%	$49.3M-27.6%	$68.1M
Retained Earnings	-$321.7M-5.7%	-$304.3M-9.5%	-$277.9M-23.2%	-$225.5M-31.6%	-$171.4M+41.8%	-$294.2M-38.0%	-$213.2M-39.6%	-$152.7M-51.6%	-$100.7M-180.5%	-$35.9M	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$232.0M+2.8%	$225.6M+49.5%	$150.9M+136.4%	$63.8M-17.5%	$77.4M-5.2%	$81.7M-11.4%	$92.2M-10.2%	$102.7M
Current Assets	$123.6M-22.8%	$160.1M+115.3%	$74.4M+158.0%	$28.8M-31.5%	$42.1M-8.3%	$45.9M-17.9%	$55.9M-15.0%	$65.8M
Cash & Equivalents	$11.3M-88.0%	$94.1M+615.2%	$13.2M-36.2%	$20.6M-27.5%	$28.4M+34.4%	$21.1M-19.6%	$26.3M+75.1%	$15.0M
Total Liabilities	$22.1M-19.3%	$27.4M+34.9%	$20.3M+5.9%	$19.1M-11.5%	$21.6M-3.3%	$22.4M-6.5%	$23.9M-9.2%	$26.4M
Current Liabilities	$10.0M-36.6%	$15.7M+90.0%	$8.3M+22.0%	$6.8M-23.8%	$8.9M-4.1%	$9.3M-11.5%	$10.5M-9.5%	$11.6M
Total Equity	$209.9M+5.9%	$198.3M+51.7%	$130.7M+192.3%	$44.7M-19.9%	$55.8M-5.9%	$59.3M-13.1%	$68.2M-10.6%	$76.3M
Retained Earnings	-$353.7M-4.4%	-$338.7M-5.3%	-$321.7M+2.9%	-$331.4M-3.8%	-$319.2M-1.5%	-$314.5M-3.4%	-$304.3M-3.1%	-$295.0M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

OVID Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

OVID quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Operating Cash Flow	-$54.8M	-$38.3M+31.5%	-$56.0M-22.2%	-$45.8M+17.1%	-$55.2M-146.6%	$118.6M+329.9%	-$51.6M-1.0%	-$51.1M-12.1%	-$45.6M-44.8%	-$31.5M-76.8%	-$17.8M-224.5%	-$5.5M
Capital Expenditures	N/A	$0-100.0%	$71K+77.5%	$40K-96.7%	$1.2M+565.4%	$184K+44.6%	$127K+122.6%	$57K+68.7%	$34K-12.9%	$39K+28.1%	$30K-5.4%	$32K
Free Cash Flow	N/A	-$38.3M+31.6%	-$56.0M-22.3%	-$45.8M+18.8%	-$56.5M-147.7%	$118.4M+329.0%	-$51.7M-1.1%	-$51.1M-12.2%	-$45.6M-44.7%	-$31.5M-76.7%	-$17.8M-223.2%	-$5.5M
Investing Cash Flow	-$147.8M	-$49.9M-191.3%	$54.6M+2215.2%	-$2.6M+97.1%	-$87.9M-4725.0%	-$1.8M-105.3%	$34.6M+215.3%	-$30.0M-460.1%	-$5.4M-11218.8%	-$47K	N/A	N/A
Financing Cash Flow	$185.8M	$75.2M+11991.2%	$622K-98.0%	$30.5M+16802.1%	$181K-80.0%	$904K-98.1%	$47.1M-45.6%	$86.5M+30143.7%	$286K-99.6%	$66.7M	N/A	N/A
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$17.6M-26.6%	-$13.9M-33.5%	-$10.4M+19.1%	-$12.9M-169.6%	-$4.8M+53.6%	-$10.3M-2.7%	-$10.0M+33.3%	-$15.0M
Capital Expenditures	N/A	N/A	$0	$0	$0	$0-100.0%	$22K+450.0%	-$4K
Free Cash Flow	N/A	N/A	-$10.4M+19.1%	-$12.9M-169.6%	-$4.8M+53.6%	-$10.3M-2.5%	-$10.0M+33.2%	-$15.0M
Investing Cash Flow	-$86.7M-1557.8%	$6.0M+108.3%	-$72.1M-1526.1%	$5.1M-58.1%	$12.1M+136.2%	$5.1M-76.0%	$21.3M+7191.8%	$292K
Financing Cash Flow	$21.6M-75.7%	$89.0M+18.4%	$75.2M+501093.3%	$15K	$0-100.0%	$13K	$0-100.0%	$38K
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0

Not reported in any period shown, so not listed: Share Buybacks.

OVID Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

OVID quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Operating Margin	-585.2%	-10933.8%	-15122.7%	-3696.4%	59.6%	-645.4%	N/A	N/A	N/A	N/A	N/A
Net Margin	-239.9%	-4664.3%	-13341.8%	-3604.7%	59.0%	-642.3%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-13.3%+25.4pp	-38.7%+20.9pp	-59.6%-18.6pp	-40.9%-109.3pp	68.3%+254.1pp	-185.7%-99.4pp	-86.3%+47.6pp	-133.9%-56.3pp	-77.7%-32.2pp	-45.5%-26.1pp	-19.3%
Return on Assets	-11.5%+17.1pp	-28.6%+7.7pp	-36.3%-1.4pp	-34.9%-98.0pp	63.1%+169.9pp	-106.7%-31.9pp	-74.8%+34.3pp	-109.1%-36.6pp	-72.4%-30.2pp	-42.3%	N/A
Current Ratio	8.97+3.7x	5.32-4.2x	9.55-9.2x	18.79+5.9x	12.87+9.5x	3.39-4.2x	7.58+2.6x	5.01-9.7x	14.71+0.7x	14.04	N/A
Debt-to-Equity	0.16-0.2x	0.35-0.3x	0.64+0.5x	0.17+0.1x	0.08-0.7x	0.74+0.6x	0.15-0.1x	0.23+0.2x	0.070.0x	0.08	N/A
FCF Margin	-528.6%	-9898.8%	-11689.0%	-3756.6%	56.8%	-409.8%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Margin	-2141.6%	N/A	-1712.1%	-9487.1%	-80.9%	-9653.9%	-14111.8%	-7645.1%
Net Margin	-2047.6%	N/A	1347.8%	-9210.6%	-74.7%	-7873.1%	-12132.9%	-8096.0%
Return on Equity	-7.1%+1.4pp	-8.6%-16.0pp	7.4%+34.6pp	-27.2%-18.8pp	-8.4%+8.9pp	-17.3%-3.8pp	-13.5%+4.8pp	-18.4%
Return on Assets	-6.5%+1.1pp	-7.5%-13.9pp	6.4%+25.4pp	-19.0%-13.0pp	-6.0%+6.5pp	-12.5%-2.5pp	-10.0%+3.6pp	-13.6%
Current Ratio	12.39+2.2x	10.17+1.2x	8.97+4.7x	4.24-0.5x	4.72-0.2x	4.93-0.4x	5.32-0.3x	5.66
Debt-to-Equity	0.110.0x	0.140.0x	0.16-0.3x	0.430.0x	0.390.0x	0.380.0x	0.350.0x	0.35
FCF Margin	N/A	N/A	-1449.6%	-9751.5%	-76.1%	-7907.7%	-13197.4%	-8676.9%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Xbiotech XBIT

$69.2M

Atara Biotherape ATRA

$92.3M

Quince QNCX

$34.3M

Entera Bio Ltd ENTX

$524.6M

Opus Genetics IRD

$307.0M

Where Ovid Therapeutics Inc Ranks

Frequently Asked Questions

What is Ovid Therapeutics Inc's annual revenue?

Ovid Therapeutics Inc (OVID) reported $7.3M in total revenue for fiscal year 2025. This represents a 1181.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ovid Therapeutics Inc's revenue growing?

Ovid Therapeutics Inc (OVID) revenue grew by 1181.3% year-over-year, from $566K to $7.3M in fiscal year 2025.

Is Ovid Therapeutics Inc profitable?

No, Ovid Therapeutics Inc (OVID) reported a net income of -$17.4M in fiscal year 2025.

What is Ovid Therapeutics Inc's EBITDA?

Ovid Therapeutics Inc (OVID) had EBITDA of -$42.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ovid Therapeutics Inc's return on equity (ROE)?

Ovid Therapeutics Inc (OVID) has a return on equity of -13.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ovid Therapeutics Inc's free cash flow?

Ovid Therapeutics Inc (OVID) recorded an outflow of $38.3M in free cash flow during fiscal year 2025. This represents a 31.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ovid Therapeutics Inc's operating cash flow?

Ovid Therapeutics Inc (OVID) recorded an outflow of $38.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Ovid Therapeutics Inc's total assets?

Ovid Therapeutics Inc (OVID) had $150.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ovid Therapeutics Inc's capital expenditures?

Ovid Therapeutics Inc (OVID) reported no capital expenditure during fiscal year 2025.

How much does Ovid Therapeutics Inc spend on research and development?

Ovid Therapeutics Inc (OVID) invested $25.6M in research and development during fiscal year 2025.

How many shares does Ovid Therapeutics Inc have outstanding?

Ovid Therapeutics Inc (OVID) had 132M shares outstanding as of fiscal year 2025.

What is Ovid Therapeutics Inc's current ratio?

Ovid Therapeutics Inc (OVID) had a current ratio of 8.97 as of fiscal year 2025, which is generally considered healthy.

What is Ovid Therapeutics Inc's debt-to-equity ratio?

Ovid Therapeutics Inc (OVID) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ovid Therapeutics Inc's return on assets (ROA)?

Ovid Therapeutics Inc (OVID) had a return on assets of -11.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Ovid Therapeutics Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Ovid Therapeutics Inc (OVID) held $90.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $38.3M over that year. Dividing the one by the other, the reported balance equals about 28 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Ovid Therapeutics Inc's Altman Z-Score?

Ovid Therapeutics Inc (OVID) has an Altman Z-Score of 12.84, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ovid Therapeutics Inc's Piotroski F-Score?

Ovid Therapeutics Inc (OVID) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ovid Therapeutics Inc's earnings high quality?

Ovid Therapeutics Inc (OVID) reported a net loss of $17.4M while operations used $38.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Ovid Therapeutics Inc?

Ovid Therapeutics Inc (OVID) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.